Kornimate/medical-research-clean huggingface dataset:
dietary oil to improve sleep quality

Conditions: Insomnia Type; Sleep Disorder

Summary: the purpose of this study is to identify if healthy cookies high in linoleic acid can change sleep quality and sleep architecture, blood fatty acid composition and be consumed with high compliance after eight weeks of consumption. the hypothesis is that consumption of healthy cookies for 8 weeks will improve sleep quality, increase linoleic acid in the blood and be consumed with greater than 80% compliance.

overall, linoleic acid has many health benefits including altering body composition and energy metabolism, but is not clear if linoleic acid consumption can influence sleep quality. the investigators plan to test the central hypothesis and accomplish the overall objective of this research by pursuing the following specific aims aim 1) to determine the effect of healthy cookies made with linoleic acid-rich oil on measures of sleep quality and sleep architecture in overweight adults aim 2) to determine the effect on plasma fatty acid composition and markers of circadian rhythm in peripheral blood mononuclear cells (pbmc) after four and eight weeks of consuming one healthy cookie per day aim 3) to measure the effect of healthy cookies made with la-oil on change of lipidomic profiles of plasma and pbmc after four and eight weeks of consumption aim 4) to determine the feasibility of adherence to consuming 1 healthy cookie per day in place of snack for eight weeks

Eligibility criteria:
inclusion criteria: * overweight (bmi ≥25 and \<38) * nonsmoker * insomnia severity index score ≥8 exclusion criteria: * current or previous diagnosis of diabetes, heart (including stroke or heart attack), kidney, liver or circulatory diseases and/or current treatment for cancer * gastrointestinal diseases or disorders (including pancreatic) or gastric bypass surgery * food allergy or intolerance * any dietary restriction where consumption of these healthy cookies or any ingredient would be contraindicated * use of medications where consuming the healthy cookies would be contraindicated * usage of sleep aid (prescription medication(s)) for insomnia * pregnancy
comparison of efficacy in sbrt of large hcc with or without tace

Conditions: Large HCC Patients; Stereotactic Body Radiation Therapy; Transcatheter Arterial Chemoembolization

Summary: the study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.the investigators will optimize the combined treatment schedule of sbrt for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.


Eligibility criteria:
inclusion criteria: * primary hcc diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of hcc or by pathology * single lesion and longest tumor diameter were 5-10cm; * cp-a or b classification; * eastern cooperative oncology group (ecog) score 0-1; * distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm * unsuitable for other therapies, such as patients with heart disease, uncontrolled diabetes, uncontrolled hypertension, etc. * rejecting other therapies such as resection, liver transplantation, etc. * platelet count≥50 × 109/l, white blood count≥1.5 × 109/l; * patients infected with hepatitis b virus who are treated with adefovir or entecavir; patients infected with hepatitis c virus whose hcv dna are negative. exclusion criteria: * tumor thrombus; * lymph node involvement; * extrahepatic metastasis.

Keywords: cyberknife sbrt large hcc prognosis
effect of the alpha-galacto-oligasaccharides on weight loss in overweight or moderately obeses adults : a randomized controlled double blinded trial versus placebo

Conditions: Randomized Versus Placebo; Controlled; Double Blind

Summary: clinical intervention on overweight or moderately obeses adults. the objective of this trial is to demonstrate the superior eficacy of alphagos to placebo on weight loss during a low-calorie diet of 12 weeks. the superiority is judged on body weight. change in cardiometabolic risk factors through the intervention have been evaluated as secondary endpoints


Eligibility criteria:
inclusion criteria: * body mass index \> or equal 25 and \< 35 * use of effective contraception in women of childbearing age exclusion criteria: * pregnant women (positive pregnancy test) or breastfeeding * anti-hypertensive or cholesterol treatment * hiv infection or hcv * hepatic and/or severe renal failure * heart attack within 6 months prior the selection * heart failure known * inflammatory disease known * cancer or have had cancer within 3 years prior to the study except for basal cell skin cancers * diabetes defined by blood glucose greater than or equal to 1.26 g/l * gastrointestinal disease known * bariatric surgery
usefulness of a 2-hour delta troponin-i during the ed identification and exclusion of acute myocardial infarction

Conditions: Acute Coronary Syndrome

Summary: 1. in chest pain patients with suspected acute coronary syndrome, a 2-hr delta troponin-i as measured by the i-stat immunoassay reliably identifies and excludes an acute myocardial infarction. 2. in chest pain patients with suspected acute coronary syndrome whose baseline troponin is above the 99th percentile but less than 0.2ng/ml, a 2hr delta troponin-i as measured by the i-stat immunoassay accurately discriminates between acute myocardial infarction and non-acute myocardial infarction troponin elevations.

primary aims: 1) demonstrate that a 2hr delta troponin as measured by the i-stat platform can reliably identify and exclude mi on the initial ed evaluation. 2)demonstrate that a 2hr delta troponin is useful in the discrimination ami versus non-ami conditions in patients with low abnormal baseline troponin-i values. secondary aims: 1) demonstrate that a positive 2-hr delta troponin-i identifies patients at highest risk for 30 day ace. 2) other secondary aims tbd.

Eligibility criteria:
inclusion criteria: 1. adult patients 18 years of age or older 2. chest pain suspicious for acs 3. absence of st-segment elevation ami (stemi) or stemi equivalent on the initial ecg 4. baseline i-stat troponin less or equal to 1.0 ng/ml 5. enrollment initiated before 2 hour 'delt' troponin value available for review 6. ability and willingness to participate and cooperate with telephone follow-up evaluations exclusion criteria: 1. st-elevation or other ecg criteria that results in the diagnosis of ami and results in patient being sent for percutaneous coronary interventions (pci) or being treated with thrombolytics 2. patients with chest pain not deemed to warrant cardiac screening 3. blunt chest trauma 4. tachyarrhythmia (ventricular tachycardia, supraventricular tachycardia, or rapid atrial fibrillation) 5. cardiac arrest prior to arrival 6. hemodynamically unstable patients 7. pulmonary edema requiring cpap, bipap, or mechanical ventilation 8. baseline i-stat troponin measurement greater than 1.0 ng/ml 9. baseline and 2-hour i-stat troponin measurements not obtained 10. patient (or legal representative) unable or unwilling to provide written informed consent 11. subject unwilling or unlikely to comply with study procedures, including protocol-specific blood sampling 12. subject unwilling, unable, or deemed unlikely to respond or participate in telephone follow-up 13. vulnerable populations as deemed inappropriate for the study

Keywords: heart attack myocardial infarction angina chest pain
the acute effects of combined caffeine and sodium bicarbonate consumption on isometric mid-thigh pull

Conditions: Athletes

Summary: the aim of this study was to investigate the effects of isolated and combined caffeine and sodium bicarbonate consumption on acute isometric mid-thigh pull (imtp) strength, and verify whether they are cumulative, neutral or subtractive.

method: nineteen sport sciences faculty students (age 23.6±1.6 years, height 171±9.4 cm, weight 64.3±9.6 kg, fat percentage 20.5±7.3 %, bmi 21.7±2.4 kg/m2) participated and completed the intervention. this study was designed as crossover, double-blind and placebo-controlled. subjects participated under 5 crossover conditions: control (without supplement) (con), placebo (pla), caffeine (caf), sodium bicarbonate (nahco3) and caffeine+sodium bicarbonate (caf+nahco3). for caf conditions, participants consumed 6 mg/kg of caffeine, obtained from dosing the content of 200 mg capsules. as for nahco3 conditions, participants consumed 0.3 g/kg of sodium bicarbonate dissolved in water. for the combined condition, (caf+nahco3), intake was set at 6 mg of caffeine and 0.3 g of sodium bicarbonate per kilogram of body weight. all supplements were consumed 60 min before the tests. two submaximal trials of imtp were performed at increasing intensities for 5 seconds (approximately %40-60 and %60-80 of their individually perceived 1rm, respectively, with 60-second rest intervals).

Eligibility criteria:
inclusion criteria: * being physically active and healthy * did not use ergogenic supplements in the last 3 months * did not consume high doses of caffeine (≤120-170 mg/d) were included in this study exclusion criteria: * actively using supplements * did not perform maximal effort during performance tests * not using the supplements in the correct dose or vomiting after use

Keywords: caffeine sodium bicarbonate isometric contraction performance-enhancing substances
collection of human biological samples for the development and validation of new methods of diagnosis and for the realization of expertises diagnostics in the field of infectious diseases and tropical

Conditions: Infectious Disease; Tropical Disease

Summary: direct constitution of collections from various samples taken on a prospective cohort of healthy volunteers, to prepare human biological samples of known characteristics (biochemical and serological in particular) and quality controlled.

direct constitution of collection from various samples taken on a prospective cohort of healthy volunteers, to prepare human biological samples of known characteristics (biochemical and serological in particular) and quality controlled. this collection will allow, as a priority, a development stage, ie the establishment of the proof of concept of new diagnostic methods in the field of infectious and tropical diseases. there will be 2 cohorts (= arms) for this study: the main cohort of healthy volunteers and the n cohort, which will consist of patients with neuro-meningeal disease of infectious appearance and followed in specialized consultation.

Eligibility criteria:
inclusion criteria: * major subject * affiliated or benefiting from social security * having signed the information and consent form * negative hiv and hcv serology and negative hbv or vaccine serology (or old healed infection profile) * for cohort n: neuromeningeal infection during dianostic exploration exclusion criteria: * volunteers with a severe or chronic pathology significantly disturbing one or more bio-clinical parameters and / or requiring the regular intake of certain drugs (anti-inflammatories or corticosteroids for example). * woman whose pregnancy is known during the visit. * acute infection within 15 days or taking antiviral, antibiotic, antifungal or antiparasitic drugs in the last 15 days. * subject participating in a biomedical research or in a period of exclusion of a biomedical research. * when monitoring o +, ab +, a + and b + blood group whose erythrocyte base is kept for cepia research, in case of antimalarial (travel), a minimum of 5 half-lives after the last dose of antimalaria.

Keywords: sample diagnostic
short-term outcomes of sils+1 versus cls for distal gastric cancer

Conditions: Surgery

Summary: to evaluate the short-term outcomes of single-incision plus one-port laparoscopic surgery (sils + 1) versus conventional laparoscopic surgery(cls) for distal gastric cancer whose clinical stage was ct1-3n0-2m0

the gastric cancer patients with ct1-3n0-2m0 were randomized at a 1:1 ratio to the cls group or the sils+1group, then it will evaluate the short-term outcomes between two groups.

Eligibility criteria:
inclusion criteria: * pathological diagnosis of gastric cancer * clinically diagnosed ct1b-3n0-2m0 lesions according to the 8th edition of the american joint committee on cancer(ajcc) cancer staging manual(measured using abdominal ct) * tumor size ≤ 5cm * planned to conduct subtotal gastrectomy exclusion criteria: * preoperative radiotherapy and chemotherapy * tumor perforation * severe mental disease
a trial of oseltamivir in high-risk patients presenting to the emergency department with influenza

Conditions: Influenza

Summary: a multi-centre, randomized, placebo controlled, trial. participants will be patients either ≥65 years or with one or more high risk conditions presenting to one of four academic emergency departments in edmonton or calgary with influenza-like illness. the investigators will test for influenza using a point-of-care rapid test and if positive for influenza participants will be randomized to oseltamivir or placebo and followed prospectively. the primary outcome will be hospitalization.


Eligibility criteria:
inclusion criteria: * outpatient at the university of alberta hospital, the northeast community centre, foothills medical centre, rockyview general hospital emergency departments * ≥ 18 years of age * ≥ 65 years of age or chronic cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis, and asthma) , diabetes mellitus and other metabolic diseases, cancer, immunodeficiency, immunosuppression (due to underlying disease and/or therapy), renal disease, anemia, and hemoglobinopathy, any condition that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration * acute respiratory infection (ari) exhibiting 2 or more symptoms, onset within last 72 hours * laboratory confirmation of influenza infection, onset within last 72 hours exclusion criteria: * contraindication to oseltamivir (i.e., previous anaphylaxis) * resident of a nursing home * canadian triage and acuity scale (ctas) 1 * blood pressure \< 90 mmhg * respiratory rate \>30 breaths per minute * pao2 less \<88% * confusion * inability to eat or drink * radiographic evidence of pneumonia

Keywords: antiviral oseltamivir
study of oral rapamycin plus bare metal stents vs drug eltuting stents

Conditions: Coronary Heart Disease; Coronary Restenosis

Summary: in a previous randomized comparison oral sirolimus plus bare metal stent compared to bare metal stent implantation alone demonstrated at one year of follow up a significant reduction of angiographic and clinical parameters of restenosis (anmat resolution number 3366 from june 2004 and rodriguez a et al jacc,2006,47,1522-1529). in addition previous reported registries from our group with drug eluting stents showed similar amount of reduction in clinical parameters (not angiographic)of restenosis (eraci iii, rodriguez a et al eurointervention 2006,2:53-60). taking in account that 8.3% of patients treated with oral rapamycin plus bare metal stents(orar ii trial jacc 2006)and 8.8% of patients treated with des developed clinical restenosis (eraci iii registry, eurointervention 2006) the investigators sought to compare differences in overall cost with both revascularization strategies at 1, 2, 3 and 5 years of follow up assuming that safety and efficacy clinical end points would be similar.

patients with de novo lesions treated in different institutions in buenos aires argentina were randomized to treat with oral sirolimus plus bare metal stent implantation (100 patients) or des(100 patients).

Eligibility criteria:
inclusion criteria: * indication of revascularization * de novo lesions * native vessels * suitable for stent placement exclusion criteria: * acute myocardial infarction within the last 24 hours * in stent restenosis * previous percutaneous coronary intervention within the last 6 months

Keywords: drug eluting stents stents bare metal stent thrombosis coronary revascularization survival
characterization of dupex2 duchenne muscular dystrophy

Conditions: Muscular Dystrophy, Duchenne

Summary: to characterize the clinical phenotype and possible predictive/prognostic factors of patients with duchenne muscular dystrophy (dmd) due to duplication of exon 2 (dup2). specifically, we aim 1) to describe the progression of motor, respiratory and cardiac function; 2) to enquire if the phenotypic spectrum of dup2 is milder than classic dmd, 3) to perform whole genome sequencing (wgs) to characterize dna breakpoints to correlate with the phenotype; 4) to collect material for future proteomic/transcriptomic studies. background/rationale dmd is caused by mutations in the dmd gene and in 11% of cases is due to duplications. the most promising therapeutic approaches include mutation-specific therapies. notably, there is increasing evidence that specific groups of mutations may underlie different disease trajectories compared to the "average" dmd population. it is thus mandatory to have more information on genotype-phenotype correlations and patterns of progression related to different genotypes. dup2 is the most common dmd duplication and the only one for which a aav-mediated exon skipping study is ongoing. despite most case series and databases ascribe dup2 to severe phenotype, our preliminary findings sustain that these patients have collectively a milder progression of the disease and in 1/3 of cases a significantly milder phenotype. moreover, our attempts to reveal mechanism involved in attenuating the phenotype would confute the hypothesis of alternative spicing transcripts as previously described for dmd with deletion of exon 2. research design and methods clinical information regarding a cohort of 26 italian dup2 patients will be collected. differences in time to loss of ambulation compared to a dmd control group will be achieved. finally, we will retrieve dna for correlative wgs studies. anticipated output we expect that dup2 patients present a milder dmd phenotype , which might be predicted by genomic studies.

the primary clinical endpoint is time to loss of ambulation (loa). secondary endpoints include: 1. the change over time of the following functional measurements: 1.1 motor function: the 6 minute walk test (6mwt) and north star ambulatory assessment (nsaa) including sub-items such as time to rise from the floor. 1.2 respiratory function: forced vital capacity (fvc) liters (l) and % of predicted; time to fvc% \< 50%. time to nocturnal ventilation initiation. 1,3 cardiac function: left ventricular ejection fraction (ef) as measured by echocardiogram. 2. to characterize dna breakpoints in mild vs severe phenotypes

Eligibility criteria:
inclusion criteria: * pediatric and adult dmd patients harboring a genetically confirmed duplication of the exon 2 in the dystrophin gene exclusion criteria: * patients lacking genetic confirmation of dup2 mutation
a study of ct-868 in type 1 diabetes mellitus

Conditions: Overweight; Obese; Type 1 Diabetes Mellitus

Summary: this study will evaluate the changes in glycemic control in overweight and obese adults with type 1 diabetes mellitus after receiving ct-868 for 16 weeks. the effectiveness and safety of ct-868 will be compared to placebo. all participants will continue with their standard diabetes care using either an insulin pump (csii) or multiple daily injections (mdi). alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. treatment assignments, either ct-868 plus insulin or placebo plus insulin will be randomly determined.


Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or older at the time of signing informed consent * have a documented clinical diagnosis of t1dm greater than or equal to 1 year before the screening visit * body mass index greater than or equal to27.0 kg/m2 * hemoglobin a1c (hba1c) level between 7.0% and 10.0%, inclusive, at the screening visit exclusion criteria: * diagnosis of type 2 diabetes mellitus (t2dm) or any other types of diabetes, except t1dm * experienced diabetic ketoacidosis (dka) within 3 months prior to the screening visit * experienced severe hypoglycemia (level 3 as defined in the ada standards of medical care in diabetes (ada 2022) within 3 months prior to the screening visit
the link between "time in range" versus hba1c and the presence of chronic complications in type 1 diabetes: a longitudinal study

Conditions: Diabetes Mellitus, Type 1

Summary: hba1c is currently the only metric of glucose control showing an association with chronic complications of type 1 diabetes mellitus (t1d). time in range (tir, 70-180 mg/dl) measured by real-time continuous glucose monitoring (cgm) might be a better marker. in this study, the investigators studied the clinical significance of a 10% increase of tir over two years.

adult subjects (age ≥ 18 years) with t1d were consecutively recruited in three multicenter studies (rescue, future, alertt1 studies) organized between september 2014 and 19 november 2021. for the tirco study, only the data from patients recruited at the university hospital of antwerp were analyzed. initially, the data from 498 patients were collected. pregnant patients and patients with beta-cell transplantation were excluded from the study, resulting in the inclusion of 479 patients. consecutive patients starting cgm were proposed to participate and were included into the study after signing informed consent. the study population consisted of 445 patients who used freestyle libre, 21 patients who used cgm in hybrid closed loop and 13 patients who used dexcom g4 and g6, resulting in a total of 479 patients. in this project, the investigators looked into the link between tir versus hba1c and the presence of chronic complications in adults with t1d. the primary endpoint was to evaluate the link between tir and the presence of chronic microvascular complications as formulated by the following research question: "what is the clinical significance of a 10% increase of tir over two years?" the secondary endpoint was to assess the link between tir and independent risk factors for micro- and macrovascular complications such as sex, age, bmi, lipids, blood pressure, hba1c, time in range, mean glucose, diabetes duration, method of insulin administration (mdi or csii), type of sensor and sensor compliance.

Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus * using real-time continuous glucose monitoring (rtcgm), intermittently scanned cgm (iscgm) or (hybrid) closed loop (hcl) as diabetes treatment * willing to sign informed consent exclusion criteria: * pregnancy * patients that had beta-cell transplantation

Keywords: type 1 diabetes hba1c time in range chronic complications continuous glucose monitoring